HBIO President, David Green, to Present At US Bancorp Piper Jaffray Healthcare Conference

Business Wire, Jan 10, 2002

Business Editors

HOLLISTON, Mass.--(BUSINESS WIRE)--Jan. 10, 2002

Harvard Bioscience, Inc., (Nasdaq: HBIO) today announced that its President, David Green, will present at the US Bancorp Piper Jaffray Healthcare conference in New York on Thursday January 31 at 11am. The presentation will be webcast. Mr. Green will cover HBIO's three part growth strategy of innovation, acquisition and partnership; its strategic positioning at the target validation and ADMET screening bottlenecks of the drug discovery pipeline; its core technologies including recent results with it breakthrough COPAS high throughput/high content model organism screening system; recent acquisitions; and its financial performance. Requests for one-on-one interviews should be addressed to Sharon Novak, Asst. Vice-President, Capital Markets; US Bancorp Piper Jaffray, 612 303 6226.

About Harvard Bioscience, Inc.

Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells approximately 10,000 products to thousands of researchers in over 60 countries though its direct sales force, 1,000 page catalog, and through its distributors, the most notable of which is Amersham Biosciences. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Austria and Belgium with sales facilities in France and Canada. For more information please visit www.harvardbioscience.com

The statements made in this press release that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements about the impact of acquisitions on future revenues, the Company's or managements opinion of analysts' earnings estimates, the possible effect of our technology on the drug development process, the Company's intention to strengthen its market position, the Company's or management's confidence or expectations, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's products, and the Company's plans, objectives and intentions contained in this press release that are not historical facts. Other factors that may cause the Company's actual results to differ materially from those in the forward looking statements include the Company's failure to successfully integrate an acquired business or technology, expand its product offering, to introduce new products or to commercialize new technologies or decreased demand for the Company's products due to changes in our customers needs, financial position, general economic outlook, or otherwise, as well as those set forth under the heading "Important Factors That May Affect Future Operating Results" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2000, as well as other risks described in the Company's public filings or factors, if any, of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information.